Clinical Trial: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Study Status: Available
Recruit Status: Available
Study Type: Expanded Access

Official Title: An Open Label, MultiCenter, Expanded-Access Program for Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Brief Summary: The primary objective of this expanded access program is to provide ocrelizumab as treatment for eligible participants with primary progressive multiple sclerosis (PPMS) before it is commercially available in the United States (U.S.) for the indication of PPMS.

Detailed Summary:
Sponsor: Genentech, Inc.

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Genentech, Inc.

Dates:
Date Received: June 16, 2016
Date Started:
Date Completion:
Last Updated: May 8, 2017
Last Verified: May 2017